In conclusion, our data suggest that inhibiting MCT-1 could be a potential strategy as a targeted therapy for non-small cell lung cancers, especially for gefitinib-resistant NSCLC. The gene discussed is SLC16A1; the disease is non-small cell lung carcinoma.